Aug 11, 2017

Peptide Based Cancer Therapeutics Market To Surpass A Valuation of US$ 11,100 Mn Over 2022

by Team Fact.MR

Popularity of peptide based cancer therapeutics is on the rise, owing to the positive outlook on their efficiency in treating cancer. According to the latest report published by Fact.MR, the global market for peptide based cancer therapeutics is set to reflect an above average CAGR during 2017 to 2022, to reach a valuation in excess of US$ 11,100 Mn. Incessant development in drug modification, stability, delivery and preclinical achievements is reflecting positively on the future prospects of the global peptide based cancer therapeutics market. Of late, an array of new peptides with encouraging preclinical results are undergoing clinical trials for treating cancer. At the same time, these new peptide are also finding application in various other therapeutic areas. Also, increasing occurrence of cancer is anticipated to be instrumental in boosting the demand for peptide based cancer therapeutics in the near future. As per WHO, over 8 million deaths were recorder globally due to cancer in 2015. Cancer remains one of the foremost causes of death around the world. Factors mentioned above are projected to make a significant influence on the global market for peptide based cancer therapeutics over the forecast period. Moreover, low potency of conventional cancer therapeutics and the adverse side-effects from these therapeutics is prompting physicians to utilise other options.  This, in turn, is facilitating the adoption of new-age peptide based therapeutic drugs.

Forecast Highlights Of Global Market For Peptide Based Cancer Therapeutics

  • Among regions, North America is expected to remain the most attractive market for peptide based cancer therapeutics during the forecast period. This is largely due to the existence of several prominent peptide based cancer therapeutic drug makers and an advanced healthcare infrastructure in the region. Over the next couple of years, the region’s market is projected to witness a healthy growth. Meanwhile, the market in Asia-Pacific excluding Japan (APEJ) is anticipated to register the fastest CAGR over 2022.
  • Based on drugs, demand for bortezomib is expected to remain relative higher as compared to other peptide based cancer therapeutic drugs.  Revenues from global sales of bortezomib drugs currently commands for nearly 40% market share.  Towards the end of 2022, more than US$ 4,700 Mn worth bortezomib drugs are estimated to be sold worldwide.
  • Hospital pharmacies are the largest distribution channel for peptide based cancer therapeutic drugs followed by retail pharmacies. Currently, hospital pharmacies account for close to 50% share of the global market in terms of revenue. The trend is likely to continue in 2017 and beyond.

Competition Tracking

Valeant Pharmaceuticals International, Inc., Allergan plc, AbbVie Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Abbott, Pfizer Inc., and Johnson & Johnson are among the leading companies functioning in the global market for peptide based cancer therapeutics. Majority of these market players are actively focusing on further product development as well as channelizing their investments in R&D activities.